CompanyRCUSNYSEHayward, CA

Arcus Biosciences, Inc.

Arcus Biosciences develops small-molecule inhibitors for cancer, inflammatory, and autoimmune diseases.

SEC EDGAR ClinicalTrials.gov arcusbio.com

DEF 14AAug 7Latest SEC filing, period to Sep 9

Aug 7Latest story

August 2026

Arcus casdatifan: two new trials recruiting, hepatic PK study and RCC gene expression pilot

Aug 7Weekly roundup, 2 itemsArcus Biosciences, Inc.casdatifan

Arcus Biosciences advances casdatifan combinations, reports $775M cash at midyear 2026

Aug 5Quarterly updateArcus Biosciences, Inc.AstraZeneca